Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients [Phase 3]
A Phase 3 trial evaluating sildenafil for Eisenmenger-associated pulmonary arterial hypertension has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-05-17Clinical Trial Update: The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil [Phase 1]
Phase 1 pharmacokinetic study assessing the effect of renal impairment on the pharmacokinetics of oral treprostinil in pulmonary arterial hy…
-
CLINICAL_TRIALS withdrawal · 2012-05-14Clinical Trial Update: A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor [Phase 3]
A Phase 3 multinational trial evaluating BPS-314d-MR for pulmonary arterial hypertension has been withdrawn; no study results are reported.
-
CLINICAL_TRIALS trial_result · 2012-04-24Clinical Trial Update: A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension [Phase 3]
A long-term, open-label Phase 3 safety study of sitaxsentan sodium in pulmonary arterial hypertension was terminated, with results posted in…
-
CLINICAL_TRIALS withdrawal · 2012-03-26Clinical Trial Update: Inhaled Treprostinil for PAH: Open-label Extension [Phase 3]
A Phase 3 open-label extension trial of inhaled treprostinil for pulmonary arterial hypertension has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2012-03-26Clinical Trial Update: Safety and Efficacy of Inhaled Treprostinil in Patients With PAH [Phase 3]
Phase 3 trial evaluating inhaled treprostinil for pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-03-09Clinical Trial Update: Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
This completed clinical trial from Medical University of Graz explored early recognition of pulmonary arterial hypertension in patients with…
-
CLINICAL_TRIALS trial_result · 2012-03-01Clinical Trial Update: Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS) [Phase 3]
Phase 3 trial evaluating sitaxsentan for pulmonary arterial hypertension with an assessment of adding sildenafil; the study was terminated a…
-
CLINICAL_TRIALS trial_result · 2012-02-29Clinical Trial Update: Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil [Phase 3]
Phase 3 trial comparing sitaxsentan plus sildenafil versus sitaxsentan alone in pulmonary arterial hypertension was terminated. Results were…
-
CLINICAL_TRIALS trial_result · 2012-02-22Clinical Trial Update: A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses [Phase 1]
Phase 1 pharmacokinetic drug–drug interaction study evaluating sitaxsentan with sildenafil and sitaxsentan with tadalafil in pulmonary arter…
-
CLINICAL_TRIALS trial_result · 2012-02-20Clinical Trial Update: Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety [Phase 3]
Phase 3 trial evaluating monotherapy and combination therapy with sitaxsentan for pulmonary arterial hypertension; study terminated with res…
-
CLINICAL_TRIALS trial_result · 2012-02-17Clinical Trial Update: Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers [Phase 1]
Phase 1 dose-finding, safety, and pharmacodynamic study of inhaled sodium nitrite solution in healthy volunteers.
-
FDA approval · 2012-02-15FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approves a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2012-02-13Clinical Trial Update: A Study to Evaluate GSK1325760A - a Long-Term Extension Study [Phase 3]
This clinical trial update reports the completion and posting of results for a Phase 3 long-term extension study evaluating GSK1325760A. The…
-
CLINICAL_TRIALS trial_result · 2012-02-07Clinical Trial Update: Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
A Mayo Clinic-sponsored study evaluated whether lisinopril modulates the activity of sildenafil in patients with pulmonary arterial hyperten…
-
CLINICAL_TRIALS trial_result · 2012-02-01Clinical Trial Update: A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin
A non-interventional registry was established to collect predefined safety data from patients prescribed Thelin (treprostinil) for pulmonary…
-
CLINICAL_TRIALS trial_result · 2012-01-27Clinical Trial Update: Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension [Phase 2]
This document reports results from a Phase 2 extension study of ambrisentan in pulmonary arterial hypertension, with results posted in Janua…
-
CLINICAL_TRIALS trial_result · 2012-01-12Clinical Trial Update: The Early Recognition of Pulmonary Arterial Hypertension [NA]
A completed clinical trial from the Medical University of Graz investigating early recognition of Pulmonary Arterial Hypertension.
-
CLINICAL_TRIALS trial_result · 2011-12-14Clinical Trial Update: Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients [Phase 3]
Phase 3 long-term open-label safety study of sitaxentan sodium in Japanese patients with pulmonary arterial hypertension was terminated; res…
-
CLINICAL_TRIALS trial_result · 2011-12-01Clinical Trial Update: A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients [Phase 3]
A Phase 3 safety and efficacy study of sitaxentan sodium in Japanese patients with pulmonary arterial hypertension was terminated; trial res…
-
CLINICAL_TRIALS trial_result · 2011-09-23Clinical Trial Update: Early Therapy of Pulmonary Arterial Hypertension [NA]
This entry reports a completed clinical trial evaluating early therapy for pulmonary arterial hypertension. The trial was sponsored by the M…
-
CLINICAL_TRIALS trial_result · 2011-08-30Clinical Trial Update: Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II [Phase 3]
Phase 3 trial update reporting efficacy and safety data for oral bosentan in patients with pulmonary arterial hypertension class II.
-
CLINICAL_TRIALS trial_result · 2011-07-20Clinical Trial Update: Placebo Controlled Trial of Bosentan in Scleroderma Patients [Phase 2]
A phase 2 placebo-controlled trial of bosentan in patients with systemic sclerosis and pulmonary hypertension was terminated; results were p…
-
FDA approval · 2011-07-19FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2011-06-28Clinical Trial Update: Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease
Clinical trial update on using iloprost to treat adults with pulmonary arterial hypertension associated with congenital heart disease.